Seagen/Genmab's Tivdak Set To Take On Merck’s Keytruda

 
• By Joseph Haas

Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.

Businessman Success. A businessman launching upwards, paperwork flying everywhere!
Seagen gets its fourth FDA approval and third ADC with Tivdak okay

More from New Products

More from Scrip